Cargando…

Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study

Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID-19 in fragile and immunocompromised patients. In this real-life, prospective, observational study, we evaluated efficacy and safety of a 3-day early treatment with remdesivir in adult and fragile patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Scotto, Riccardo, Buonomo, Antonio Riccardo, Iuliano, Antonio, Foggia, Maria, Sardanelli, Alessia, Villari, Riccardo, Pinchera, Biagio, Gentile, Ivan, Federico II COVID-Team
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964994/
https://www.ncbi.nlm.nih.gov/pubmed/36851078
http://dx.doi.org/10.3390/vaccines11020200
_version_ 1784896646910312448
author Scotto, Riccardo
Buonomo, Antonio Riccardo
Iuliano, Antonio
Foggia, Maria
Sardanelli, Alessia
Villari, Riccardo
Pinchera, Biagio
Gentile, Ivan
Federico II COVID-Team,
author_facet Scotto, Riccardo
Buonomo, Antonio Riccardo
Iuliano, Antonio
Foggia, Maria
Sardanelli, Alessia
Villari, Riccardo
Pinchera, Biagio
Gentile, Ivan
Federico II COVID-Team,
author_sort Scotto, Riccardo
collection PubMed
description Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID-19 in fragile and immunocompromised patients. In this real-life, prospective, observational study, we evaluated efficacy and safety of a 3-day early treatment with remdesivir in adult and fragile patients with a diagnosis of SARS-CoV-2 infection who referred to the COVID-19 early treatment service of Infectious Diseases Unit of University of Naples Federico from 10 January 2022 to 31 March 2022. The included patients could be treated with either remdesivir alone or with remdesivir plus a monoclonal antibody with activity against SARS-CoV-2. Among the 62 included patients, we showed low rates of hospitalization (8%), increase in oxygen supplementation (3.2%), ICU admission (1.6%) and death (1.6%). The rate of disease progression was 8% and it was similar in patients treated with remdesivir alone or in combination with monoclonal antibodies (6.7% and 9.4%, respectively; p = 0.531). The rate of adverse drug reaction was low and similar in the two groups (13.3% in patients treated with remdesivir, 15.6% in patients treated with the combination; p = 0.543). Most common adverse events were headache and fever. In conclusion, in our cohort of patients at a high risk of worse COVID-19 outcomes, an early course of remdesivir showed low rates of disease progression and adverse drug reactions.
format Online
Article
Text
id pubmed-9964994
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99649942023-02-26 Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study Scotto, Riccardo Buonomo, Antonio Riccardo Iuliano, Antonio Foggia, Maria Sardanelli, Alessia Villari, Riccardo Pinchera, Biagio Gentile, Ivan Federico II COVID-Team, Vaccines (Basel) Article Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID-19 in fragile and immunocompromised patients. In this real-life, prospective, observational study, we evaluated efficacy and safety of a 3-day early treatment with remdesivir in adult and fragile patients with a diagnosis of SARS-CoV-2 infection who referred to the COVID-19 early treatment service of Infectious Diseases Unit of University of Naples Federico from 10 January 2022 to 31 March 2022. The included patients could be treated with either remdesivir alone or with remdesivir plus a monoclonal antibody with activity against SARS-CoV-2. Among the 62 included patients, we showed low rates of hospitalization (8%), increase in oxygen supplementation (3.2%), ICU admission (1.6%) and death (1.6%). The rate of disease progression was 8% and it was similar in patients treated with remdesivir alone or in combination with monoclonal antibodies (6.7% and 9.4%, respectively; p = 0.531). The rate of adverse drug reaction was low and similar in the two groups (13.3% in patients treated with remdesivir, 15.6% in patients treated with the combination; p = 0.543). Most common adverse events were headache and fever. In conclusion, in our cohort of patients at a high risk of worse COVID-19 outcomes, an early course of remdesivir showed low rates of disease progression and adverse drug reactions. MDPI 2023-01-17 /pmc/articles/PMC9964994/ /pubmed/36851078 http://dx.doi.org/10.3390/vaccines11020200 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Scotto, Riccardo
Buonomo, Antonio Riccardo
Iuliano, Antonio
Foggia, Maria
Sardanelli, Alessia
Villari, Riccardo
Pinchera, Biagio
Gentile, Ivan
Federico II COVID-Team,
Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study
title Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study
title_full Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study
title_fullStr Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study
title_full_unstemmed Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study
title_short Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study
title_sort remdesivir alone or in combination with monoclonal antibodies as an early treatment to prevent severe covid-19 in patients with mild/moderate disease at high risk of progression: a single centre, real-life study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964994/
https://www.ncbi.nlm.nih.gov/pubmed/36851078
http://dx.doi.org/10.3390/vaccines11020200
work_keys_str_mv AT scottoriccardo remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy
AT buonomoantonioriccardo remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy
AT iulianoantonio remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy
AT foggiamaria remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy
AT sardanellialessia remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy
AT villaririccardo remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy
AT pincherabiagio remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy
AT gentileivan remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy
AT federicoiicovidteam remdesiviraloneorincombinationwithmonoclonalantibodiesasanearlytreatmenttopreventseverecovid19inpatientswithmildmoderatediseaseathighriskofprogressionasinglecentrereallifestudy